Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Deloitte
Teva
Julphar
McKinsey
US Army

Generated: July 23, 2019

DrugPatentWatch Database Preview

Capromab pendetide - Biologic Drug Details

Try a free trialSee Plans and Pricing

« Back to Dashboard

Summary for capromab pendetide
Tradenames:1
Patents:9
Applicants:1
BLAs:1

US Patents for capromab pendetide

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source
Cytogen PROSTASCINT capromab pendetide VIAL; INTRAVENOUS 103608 001 1996-10-28 ➤ Sign Up CureVac AG (Tubingen, DE) ➤ Sign Up RX search
Cytogen PROSTASCINT capromab pendetide VIAL; INTRAVENOUS 103608 001 1996-10-28 ➤ Sign Up Spectrum Dynamics LLC (Orangeburg, NY) ➤ Sign Up RX search
Cytogen PROSTASCINT capromab pendetide VIAL; INTRAVENOUS 103608 001 1996-10-28 ➤ Sign Up AbbVie, Inc. (North Chicago, IL) ➤ Sign Up RX search
Cytogen PROSTASCINT capromab pendetide VIAL; INTRAVENOUS 103608 001 1996-10-28 ➤ Sign Up biOasis Technologies, Inc. (Vancouver, British Columbia, unknown) ➤ Sign Up RX search
Cytogen PROSTASCINT capromab pendetide VIAL; INTRAVENOUS 103608 001 1996-10-28 ➤ Sign Up AbbVie Inc. (North Chicago, IL) ➤ Sign Up RX search
Cytogen PROSTASCINT capromab pendetide VIAL; INTRAVENOUS 103608 001 1996-10-28 ➤ Sign Up City of Hope (Duarte, CA) ➤ Sign Up RX search
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source

Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for capromab pendetide

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0822 Netherlands ➤ Sign Up PRODUCT NAME: RITUXIMAB EN RECOMBINANT HUMAAN HYALURONIDASE; REGISTRATION NO/DATE: EU/1/98/067/003 - UITVOERINGSBESLUIT C(2014)2048 20140326
138 Luxembourg ➤ Sign Up PRODUCT NAME: RITUXIMAB ET HYALURONIDASE HUMAINE RECOMBINANTE; FIRST REGISTRATION DATE: 20140326
2016022 Lithuania ➤ Sign Up PRODUCT NAME: RITUKSIMABAS; REGISTRATION NO/DATE: EU/1/98/067/001-002 20140321
2015 00043 Denmark ➤ Sign Up PRODUCT NAME: TRASTUZUMAB OG REKOMBINANT HUMAN HYALURONIDASE; REG. NO/DATE: C(20135603) /EU/1/00/145/002 20130826
2015000061 Germany ➤ Sign Up PRODUCT NAME: TRASTUZUMAB UND RECOMBINANTE HUMANE HYALURONIDASE; REGISTRATION NO/DATE: EU/1/00/145/002 20130826
780 Luxembourg ➤ Sign Up PRODUCT NAME: TRASTUZUMAB ET HYALURONIDASE HUMAINE RECOMBINANTE; FIRST REGISTRATION DATE: 20130826
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Harvard Business School
Chinese Patent Office
Healthtrust
Baxter
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.